Search research articles
Contact Us
Filters
Showing results (51-60 of 82) with videos related to
Page
of 9
Sort By:
Journal of Immunological Methods
|
October 18, 2000
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial
C Scheibenbogen, P Romero, L Rivoltini, et al.
Melanoma Research
|
November 1, 1992
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study
F Belli, F Arienti, L Rivoltini, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 26, 1994
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
Y Kawakami, S Eliyahu, C H Delgado, et al.
Cancer Research
|
June 11, 1998
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)
D J Loftus, P Squarcina, M B Nielsen, et al.
Cancer Research
|
February 2, 1999
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy
L Rivoltini, P Squarcina, D J Loftus, et al.
Cancer Immunology, Immunotherapy : CII
|
May 1, 1993
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2
F Arienti, F Belli, L Rivoltini, et al.
Cancer Research
|
September 15, 2000
Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer
D Nagorsen, U Keilholz, L Rivoltini, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 23, 1998
Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide
D Valmori, N Gervois, D Rimoldi, et al.
British Journal of Haematology
|
June 1, 1991
Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells
C Gambacorti-Passerini, L Rivoltini, M Fizzotti, et al.
Human Gene Therapy
|
October 20, 1996
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells
F Arienti, J Sulé-Suso, F Belli, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 82) with videos related to
Sort By:
Page
of 9
Journal of Immunological Methods
|
October 18, 2000
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial
C Scheibenbogen, P Romero, L Rivoltini, et al.
Melanoma Research
|
November 1, 1992
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study
F Belli, F Arienti, L Rivoltini, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 26, 1994
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
Y Kawakami, S Eliyahu, C H Delgado, et al.
Cancer Research
|
June 11, 1998
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35)
D J Loftus, P Squarcina, M B Nielsen, et al.
Cancer Research
|
February 2, 1999
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy
L Rivoltini, P Squarcina, D J Loftus, et al.
Cancer Immunology, Immunotherapy : CII
|
May 1, 1993
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2
F Arienti, F Belli, L Rivoltini, et al.
Cancer Research
|
September 15, 2000
Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer
D Nagorsen, U Keilholz, L Rivoltini, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 23, 1998
Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide
D Valmori, N Gervois, D Rimoldi, et al.
British Journal of Haematology
|
June 1, 1991
Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells
C Gambacorti-Passerini, L Rivoltini, M Fizzotti, et al.
Human Gene Therapy
|
October 20, 1996
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells
F Arienti, J Sulé-Suso, F Belli, et al.
Page
of 9